Strive, Inc., publicly traded on NASDAQ under the ticker ASST, has announced the formal closure of its acquisition deal with Semler Scientific, marking a significant milestone in the company’s expansion strategy. This transaction notably includes Strive’s enhanced stake in bitcoin, elevating its holdings to approximately 12,797.9 bitcoins, positioning the company as the 11th-largest publicly traded corporate Bitcoin holder worldwide.
The acquisition aligns with Strive’s objective to diversify and deepen its footprint in health technology, particularly through expanding Semler Scientific’s focus on early-disease detection products. This strategic direction aims to leverage innovative diagnostic capabilities alongside Strive’s existing business lines.
Leadership shifts accompany these strategic developments, as Avik Roy assumes the role of Chief Strategy Officer. His responsibilities underscore the emphasis on extracting value from Semler Scientific’s operations and spearheading efforts to extend the scope of early-disease detection initiatives. Furthermore, Eric Semler, who formerly served as chairman of Semler Scientific, has joined Strive’s board as an independent member, reinforcing continuity and expertise within the governance framework. Concurrently, Joe Burnett, previously involved in Bitcoin strategy at Semler Scientific, has been appointed Vice President of Bitcoin Strategy, signaling an intensified focus on digital asset management within Strive’s portfolio.
Despite the acquisition’s strategic promise, Strive’s stock experienced declines through Friday’s trading session amid mixed performance across broader market indices, with the S&P 500 trending slightly upward and the Dow Jones Industrial Average declining. At close, ASST shares edged down by 0.26% to $0.96, hovering near a 52-week low of $0.38 according to Benzinga Pro data.
Technical indicators of the stock present a complex picture. Currently, the share price trades 5.2% above its 20-day simple moving average (SMA), yet lags 56.4% below the 100-day SMA, indicating struggles in gaining sustained upward momentum over the long term. The Relative Strength Index (RSI) sits at a neutral level of 50.75, signifying a balance with no distinct bullish or bearish bias. Contrasting this, the Moving Average Convergence Divergence (MACD) remains above its signal line, reflecting underlying bullish momentum in the shorter term. This juxtaposition of neutral to mixed technical signals may contribute to cautious investor sentiment.
Key technical thresholds include a resistance level at $1.00 and a support floor at $0.50, which constitute critical points for monitoring potential price movements in future sessions.
Looking forward, Strive’s forecasted earnings reflect targeted improvements. Analysts project the upcoming earnings report on March 30, 2026, to reveal an earnings per share (EPS) of -$0.01, a notable recovery from -$0.21 in the equivalent quarter of the prior fiscal year. Concurrently, revenue expectations have increased substantially from $0.21 million to $1.80 million, suggesting growth in operational performance.
Consensus among equity analysts reflects optimism. The company holds a "Buy" rating with an average price target of $1.50, signaling confidence in Strive’s capacity to deliver enhanced shareholder value underpinning the stock’s trajectory.
According to Benzinga Edge metrics, Strive merits a "High-Flyer" designation, driven particularly by strong momentum (score of 83 out of 100) with the stock outperforming the broader market indices. The quality of the company is also rated solidly at 66/100, supported by a healthy balance sheet. However, valuation considerations temper enthusiasm—Strive scores only 4/100 on value, indicating the shares trade at a substantial premium relative to comparable firms within the sector. This premium exposes investors to heightened risk if performance expectations are not met.
Given these valuations, investors are advised that while momentum favors the stock, careful risk management strategies such as tight stop-loss orders could be prudent to mitigate downside exposures associated with the stretched valuation.